Assam Reporter

The market size of Persistent Corneal Epithelial Defects is anticipated to increase during the study period (2018-30) in the 7MM

 Breaking News
  • No posts were found

The market size of Persistent Corneal Epithelial Defects is anticipated to increase during the study period (2018-30) in the 7MM

October 08
23:26 2021
The market size of Persistent Corneal Epithelial Defects is anticipated to increase during the study period (2018-30) in the 7MM
Persistent Corneal Epithelial Defects Market
The total PCEDs market size of PCED includes the market size of both the potential upcoming therapies such as Nexagon, ST266, and others, along with the current treatment modalities in the 7MM.

DelveInsight’s Persistent Corneal Epithelial Defects market report offers detailed information on current treatment practices, emerging drugs, Persistent Corneal Epithelial Defects market share of the individual therapies, current and forecasted Persistent Corneal Epithelial Defects market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Spain, Germany, Italy, and France), and Japan). 

Some of the Key Highlights from the Persistent Corneal Epithelial Defects Market Report

  • As per DelveInsight estimates, the total Persistent Corneal Epithelial Defects incidents cases was 241,452 in the 7MM in 2020.

  • Among the EU5 countries, Germany had the highest PCEDs incident cases in 2020.

  • Leading companies such as OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, and others are developing novel therapies for Persistent Corneal Epithelial Defects.

  • Key PCEDs pipeline therapies expected to launch in the upcoming years include Nexagon, ST266, RGN-259, and others.

  • Nexagon (OcuNexus Therapeutics/Eyevance Pharmaceuticals) has received Orphan Drug Designation from the FDA. It is currently in the Phase II studies for PEDs

  • RGN-259 is a sterile and preservative-free eye drop based on Thymosin beta-4 (T4) developed as a novel treatment by RegeneRx Biopharmaceuticals.

Request for PCEDs market report sample to understand more about the emerging drug landscape @ Persistent Corneal Epithelial Defects Treatment Market Analysis

Persistent Corneal Epithelial Defects: Overview

Persistent Corneal Epithelial Defects (PEDs or PCEDs) are caused by the failure of rapid re-epithelialization and closure following a corneal injury within 10-14 days, even with standard supportive treatment. PED awareness has grown in recent years due to increased research activities across the spectrum of ophthalmology research.

Persistent Corneal Epithelial Defects Epidemiology Segmentation

The Persistent Corneal Epithelial Defects report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Persistent Corneal Epithelial Defects Incident Cases

  • Persistent Corneal Epithelial Defects Gender-Based Incident Cases

  • Persistent Corneal Epithelial Defects Etiology-Specific Incidence

Persistent Corneal Epithelial Defects Therapeutics Market

The current PCEDs treatment approaches include Aggressive Lubrication, Punctal Occlusion, Bandage Soft Contact Lens, Pressure Patching, Tetracyclines, Prophylactic Topical Antibiotics, and Steroids. Whereas, Amniotic Membrane Grafting, Autologous Serum, Scleral Contact Lenses, and other treatments are used to treat refractory cases.

Persistent Corneal Epithelial Defects Market Outlook

The total PCEDs market size of PCED includes the market size of both the potential upcoming therapies such as Nexagon, ST266, RGN-259, and others, along with the current treatment modalities in the 7MM.

Discover more about the future market share of the drugs @ Persistent Corneal Epithelial Defects Market Share

Persistent Corneal Epithelial Defects Pipeline Therapies and Key Companies 

  • Nexagon: OcuNexus Therapeutics/ Eyevance Pharmaceuticals

  • ST266: Noveome Biotherapeutics

  • RGN-259: RegeneRx Biopharmaceuticals

Persistent Corneal Epithelial Defects Market Drivers

  • Increasing R&D activities

  • Emerging PCEDs Pipeline

  • Available Standard Therapies

Persistent Corneal Epithelial Defects Market Barriers

  • Lack of approved Therapies in the market

  • Challenges in Drug Delivery

  • Lack of Animal models

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)

Study Period: 2018-30

Persistent Corneal Epithelial Defects Key Companies: OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, among others. 

Persistent Corneal Epithelial Defects Key Pipeline Therapies: Nexagon, ST266, RGN-259, and others.

Persistent Corneal Epithelial Defects Segmentation: By Geography, By Persistent Corneal Epithelial Defects therapies

Analysis: Comparative and conjoint analysis of Persistent Corneal Epithelial Defects emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents

1.

Key Insights

2.

Report Introduction

3.

Persistent Corneal Epithelial Defects Market Overview at a Glance

4.

Executive Summary of Persistent Corneal Epithelial Defects

5.

Organizations contributing towards Persistent Epithelial Defect (PED)

6.

Persistent Corneal Epithelial Defects Disease Background and Overview

7.

Persistent Corneal Epithelial Defects Unmet Needs

8.

Persistent Corneal Epithelial Defects Epidemiology and Patient Population

9.

Persistent Corneal Epithelial Defects Current Treatment Practices

10.

Patient Journey

11.

Case Report

12.

Persistent Corneal Epithelial Defects Marketed Therapies

13.

Persistent Corneal Epithelial Defects Emerging Products

14.

Persistent Corneal Epithelial Defects: 7 Major Market Analysis

15.

Persistent Corneal Epithelial Defects Market Outlook

16.

Persistent Corneal Epithelial Defects Market Drivers

17.

Persistent Corneal Epithelial Defects Market Barriers

18.

KOL Views

19.

SWOT Analysis

20.

Appendix

21.

Report Methodology

22.

DelveInsight Capabilities

23.

Disclaimer

24.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Corneal Endothelial Dystrophy Market

Get a comprehensive analysis of Corneal Endothelial Dystrophy pipeline therapies and key companies such as Aerie Pharmaceuticals, Kowa Pharmaceuticals, Trefoil Therapeutics, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/

Related Articles